Tridek-One Therapeutics pioneers a platform of bispecific antibodies that agonize the CD31 ITIM inhibitory receptor to modulate cell-specific ITAM receptor activation for the treatment of a broad range of inflammatory and autoimmune diseases. The company’s lead program is a first-in-class CD31×GPVI bispecific antibody being developed for the treatment of thromboinflammatory diseases. This novel approach provides both antithrombotic and anti-inflammatory efficacy while minimizing bleeding risk, thereby addressing major critical medical unmet needs in the field. Our company is financed by leading European investors and led by an experienced management team.
| Website | https://tridekone.com |
| Employees | 14 (4 on RocketReach) |
| Founded | 2018 |
| Address | 4, Rue Thénard, Paris, Île-de-France 75005, FR |
| Technologies |
JavaScript
,
HTML
,
PHP
+10 more
(view full list)
|
| Industry | Biotechnology, Biotechnology Research, Drug Discovery, Science and Engineering, Life Science |
| Keywords | Therapeutic Antibodies, Monoclonal Antibodies, Immunotherapy, Autoimmune Diseases, Inflammatory Diseases, Checkpoint Inhibitors, Immune Modulation, Targeted Therapy, Receptor Targeting, Biologics, Drug Development, Pharmaceutical Research, First In Class, Therapeutic Proteins, Biopharmaceutical, Clinical Development, Preclinical Development |
| Competitors | 3M, Honeywell, Siemens, Schneider Electric, Emerson, Rockwell Automation, GE, ABB, Bosch, LG Electronics +41 more (view full list) |
Looking for a particular Tridek-One employee's phone or email?
Tridek-One Questions
Olivier Léger is the VP Biologics Engineering of Tridek-One.
4 people are employed at Tridek-One.
Tridek-One is based in Paris, Île-de-France.
Top Tridek-One Employees
-
1
-
Tran Trang
Director of Preclinical Research at Tridek-One
Montigny-le-Bretonneux, FR1 -
Mariangela Corsi
Research Scientist at Tridek-One
Île-de-France, France1 -
Guillaume Even
Assistant Ingénieur at Tridek-One
Châtenay-Malabry, FR1
Related Companies
